Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

>About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
(Date:7/30/2015)... Minn. , July 30, 2015 EnteroMedics ... devices using neuroblocking technology to treat obesity, metabolic diseases ... host a conference call on Thursday, August 6, 2015, ... for the second quarter ended June 30, 2015, and ... Company,s vBloc® Neurometabolic Therapy, delivered via the Maestro® System. ...
(Date:7/30/2015)... July 30, 2015 Tissue ... the regenerative medical devices company, announces that it ... wound care market as Tissue Regenix Wound Care ... Medicare administrator, First Coast Service Options Inc. ("First ... , Puerto Rico and ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3
... Nov. 23 Cumberland Pharmaceuticals Inc. ( CPIX) ... study evaluating the safety and efficacy of Caldolor ( ibuprofen ) ... was achieved for the primary endpoint of reducing fever in burn ... 61 adult burn patients with second or third degree burns covering ...
... , FORT WORTH, Texas, Nov. ... growing provider of specialty medical products, announced that it has filed it ... to illustrate the developments during the 2009 calendar year. , Q3 ... , Shareholder equity as of the Q3 2009 increased ...
Cached Medicine Technology:Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 6
(Date:7/30/2015)... , ... July 30, 2015 , ... Dale Sky Jones, ... States, will speak at the International Cannabis Professionals Expo held at the Caribe Royal ... The International Cannabis Professionals Expo is the largest medical cannabis expo in ...
(Date:7/30/2015)... ... 2015 , ... Committed to helping the next generation succeed - Mercy College ... to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call ... the support they need to think more broadly about their future. Building on what ...
(Date:7/30/2015)... IL (PRWEB) , ... July 30, 2015 , ... ... according to results from the 2015 Most Wired Survey conducted by Hospitals & Health ... integrated health system owned and operated by The Sisters of the Third Order ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life ... the go. With no water needed, the refreshing berry-flavored tablets are the perfect ... get the natural ingredients that may help with body detoxification, protection and hydration,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine ... Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected ... vendors, will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... important nutrients for the development of healthy nerves and ... among seniors, reports a new epidemiological study. ... USDA HNRCA, "we found a strong relationship between high ... and older who also had adequate levels of vitamin ...
... Cold Spring Harbor Laboratory (CSHL) have solved a decades-old ... suppressor gene, but have revealed// a master switch for ... effective cancer therapy in the future," said CSHL Associate ... was published in the February issue of Cell. ...
... study undertaken by a group of Spanish scientists, amongst ... University of Navarra and the Centre for Applied Medical ... a new line of treatment for patients with acute ... have been published in the official journal, Blood, of ...
... decade ago, Tom Todaro was talking to researchers at the Fred ... slow down tumor// growth by slowing the rate at which tumor ... not exploit the reaction in reverse and get cells to grow ... that has come up with techniques for increasing crop yields with ...
... suggests that strep infections in children may increase involuntary ... ,In an eight-month study of 693 children ... researchers found that shortly after the number of strep ... rise in involuntary movements and disruptive behaviors — symptoms ...
... thousands of doctors of Indian origin in Britain - many ... and gurudwaras - after they lost a case Friday against ... gain employment in the country's National Health Service (NHS). ... the prospect of returning home, while others waiting to find ...
Cached Medicine News:Health News:Optimum Folate and Vitamin B12 Levels Essential for Cognitive Function in Seniors 2Health News:Scientists Discover New Gene 2Health News:A New Treatment Discovered For Acute Lymphoblastic Leukemia 2Health News:Cancer Research May Help Biofuels 2Health News:Strep, Psychiatric Symptoms Possibly Linked in Some Children 2Health News:Strep, Psychiatric Symptoms Possibly Linked in Some Children 3Health News:Indian Doctors in Britain Lose Legal Battle 2Health News:Indian Doctors in Britain Lose Legal Battle 3Health News:Indian Doctors in Britain Lose Legal Battle 4
... The Finnpipette Digital Multichannel, with ... lighter work of routine laboratory ... these advanced features: Soft-touch tip ... volume pipetting (0.5-10ul models), Entire ...
Inquire...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Medicine Products: